Sarcopenic obesity is defined as a multifactorial disease in aging with decreased body
muscle, decreased muscle strength, decreased independence, increased fat mass, due to …

Physical exercise has gradually become a focus in cancer treatment due to its pronounced
role in reducing cancer risk, enhancing therapeutic efficacy, and improving prognosis. In …

In clinical trials, biochemical markers provide useful information on the drug's mode of
action, therapeutic response and side effect monitoring and can act as surrogate endpoints …

Post-acute sequelae of SARS-CoV-2 (PASC) is a significant public health concern. We
describe Patient Reported Outcomes (PROs) on 590 participants prospectively assessed …

Sarcopenic obesity is becoming a global health concern, owing to the rising older
population, causing cardiometabolic morbidity and mortality. Loss of muscle exceeding …

The prolonged immobilization associated with COVID-19 infection and the restrictions
imposed by the pandemic have determined major changes in physical activity and eating …

Fibroblast growth factor 21 (FGF21) is a stress hormone that is released from the liver in
response to nutritional and metabolic challenges. In addition to its well-described effects on …

Background Identifying sarcopenia's causally associated plasma proteins would provide
potential therapeutic targets. Methods We screened out sarcopenia-related proteins with …

Fibroblast growth factor 21 (FGF21) plays a vital role in normal eukaryotic organism
development and homeostatic metabolism under the influence of internal and external …

Sarcopenic obesity is defined as the coexistence of sarcopenia and obesity in the same
individual, characterized by of the co-presence of body fat accumulation and muscle loss …